Avillion’s team, with over 235 years of combined experience, stands at the forefront of clinical development excellence. Our professionals average more than 22 years of pharmaceutical industry experience, bringing deep expertise to every project.
This diverse group includes medical doctors, biostatisticians, quality assurance professionals, regulatory experts, and seasoned project managers. Strategically located across North America, Europe, and Asia-Pacific, our global team ensures 24/7 support and local insights.
Each team member is carefully selected for their expertise and dedication to advancing clinical development. Their collective involvement in over 90 successful drug approvals demonstrates our ability to navigate complex regulatory landscapes and deliver results.
Our approach to clinical trials embodies the Avillion Effect – a unique combination of expertise, strategy, and hands-on management that consistently outperforms industry standards.
Key components of the Avillion Effect include:
This effect extends to daily trial management, fostering a unified team approach that enhances execution speed, study setup optimisation, and accelerated patient enrolment. The result is high-quality data output and condensed timelines, crucial for streamlined execution of studies.
At Avillion, quality isn’t just a goal; it’s the foundation of our operational excellence. Our model integrates strategic partnerships with an intensive, bespoke audit programme, overseen by our Head of Quality Assurance.
This programme includes:
Our unwavering focus on quality, paired with our strategic and operational expertise, consistently results in significant time savings compared to traditional models. This is evidenced by our track record:
The Avillion Effect, combined with our quality-centric approach, ensures we deliver reliable, timely results that accelerate the path to regulatory approval and market entry.
Our seasoned drug development team, with over 235 years of combined experience, optimises clinical trials through expert oversight. We leverage best practices to accelerate site activation, patient enrolment, and study completion without compromising quality. Our track record includes completing 100% of Phase II/III trials on time, achieving all primary and key secondary endpoints.
Avillion offers tailored engagement models to suit our partners’ needs. Whether it’s our classic P&L relief model, in-licensing of assets, or collaborative work alongside biotech/pharma companies, we adapt nimbly to operate as a seamless extension of our partner’s team. Our global reach spans 31 countries, enabling efficient execution of worldwide clinical programmes.
Our unwavering focus on quality and oversight is a core Avillion advantage. We work closely with trial investigators, conducting site initiation visits, monitoring patient care and adverse events, and implementing rigorous audit programmes. This approach has resulted in exceptional data quality, with only a 6% overall discontinuation rate across 4,000+ patients in our global asthma programme.